Report : South & Central America GMP Cell Therapy Consumables Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)

At 28.0% CAGR, the South & Central America GMP Cell Therapy Consumables Market is speculated to be worth US$ 1,649.61 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the South & Central America GMP cell therapy consumables market was valued at US$ 584.43 million in 2022 and is expected to reach US$ 2,579.39 million by 2028, registering a CAGR of 28.0% from 2022 to 2028. Growing regulatory approvals for cell and gene therapy product and increase in strategic collaborations are the critical factors attributed to the South & Central America GMP cell therapy consumables market expansion.  

Academic cell GMP facilities are important for advancing immunotherapy. Hospitals and academic research institutions are the main drivers for scientific innovation and early-stage product development. Pharmaceutical companies depend majorly on hospitals and clinics for the availability of required patients to perform clinical trials using novel products and consumables. Additionally, several academic hospitals have started building their personalized patient treatment programs across the world. For instance, Tumor Infiltrating Lymphocytes (TILs) therapy, a type of immunotherapy used in clinical trials to treat advanced-stage cancer patients, has been made accessible worldwide via academic centers. The academic centers and hospitals had to meet GMP requirements, including the construction of specialized facilities for product development, manufacture, and quality control testing, as well as the establishment of a pharmaceutical quality system compliant with laws and regulations to guarantee the consistent development of high-quality products for patients. Further, the CAR cellular therapies field is newly developed, and preclinical and clinical studies have already shown remarkable results. It is believed that CAR-based cellular therapies are profoundly promising and will lead the development of approved personalized therapeutic options in the coming years. With new therapeutic modalities emerging in the cell and gene space (CAR-T), companies are required to develop, evaluate, and test these therapies in clinical trials, along with maintaining patient safety. These emerging therapies require a scientific standard of controls and GMPs to ensure patient safety. Thus, it is important to ensure that the equipment used during these processes is compatible with GMP manufacturing environments for cell therapies, and all clinical consumables are manufactured under conditions that fulfil GMP requirements appropriate for the phase and scale of manufacturing. Therefore, the increasing clinical trials among various fields will drive the South & Central America GMP cell therapy consumables market.  

On the contrary, stringent regulatory policies hurdles the growth of South & Central America GMP cell therapy consumables market.

Based on product, the South & Central America GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held 52.2% share of  South & Central America GMP cell therapy consumables market in 2022, amassing US$ 304.87 million. It is projected to garner US$ 1,327.09 million by 2028 to expand at 27.8% CAGR during 2022–2028.

Based on cell therapy, the South & Central America GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment held 56.2% share of the South & Central America GMP cell therapy consumables market in 2022, amassing US$ 328.72 million. It is projected to garner US$ 1,421.47 million by 2028 to expand at 27.6% CAGR during 2022–2028.    

Based on process, the South & Central America GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. The cell collection and characterization/sorting and separation segment held 36.3% share of  South & Central America GMP cell therapy consumables market in 2022, amassing US$ 212.13 million. It is projected to garner US$ 937.76 million by 2028 to expand at 28.1% CAGR during 2022–2028. 

Based on end use, the South & Central America GMP cell therapy consumables market is segmented into clinical, commercial, and research. The clinical segment held 75.7% share of  South & Central America GMP cell therapy consumables market in 2022, amassing US$ 442.55 million. It is projected to garner US$ 1,983.92 million by 2028 to expand at 28.4% CAGR during 2022–2028. 

Based on country, the South & Central America GMP cell therapy consumables market is segmented into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that the Rest of South & Central America captured 38.0% share of  South & Central America GMP cell therapy consumables market in 2022. It was assessed at US$ 222.26 million in 2022 and is likely to hit US$ 962.37 million by 2028, exhibiting a CAGR of 27.7% during the forecast period.

Key players dominating the South & Central America GMP cell therapy consumables market are Bio-Techne Corp, BPS Bioscience Inc, Corning Inc, FUJIFILM Irvine Scientific Inc, Global Life Sciences Solutions USA LLC, Lonza Group AG, Merck KGaA, Miltenyi Biotec BV & Co KG, Sartorius AG, and Thermo Fisher Scientific Inc, among others.

  • In June 2021, CellPoint and Lonza collaborated to rapidly develop several T-cell based therapies and utilize the Cocoon Platform for clinical point-of-care manufacturing. The goal was to provide a proof of concept for point-of-care manufacturing to reduce vein-to-vein time, decrease manufacturing costs, and minimize complex shipping logistics.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure